Key takeaways
- We found no UK legislation that names BPC-157, and the emc, the UK database of licensed medicines’ product information, returned no product containing it (18 Nov 2026).
- Selling or supplying an unauthorised medicinal product is an offence under the Human Medicines Regulations 2012, with a maximum of two years’ imprisonment, a fine or both on indictment.
- The MHRA classifies finished products, not substances, so its view depends on each product’s claims, composition, form and use.
- In 2026 the MHRA said it disregards “research purposes” claims used to avoid medicines law, and its enforcement unit announced raids in February and May on premises it believed were used to make and distribute unlicensed weight-loss medicines “as well as peptide products”.
- Sport runs on its own rulebook: WADA has named BPC-157 in class S0 since 1 January 2022.
01What does UK law say about BPC-157?
UK medicines law keeps no list of peptides. It asks what a product is, and then who may sell, supply or advertise it.
Is the product a medicine? The definition in regulation 2 of the Human Medicines Regulations 2012 has two limbs. One turns on presentation: what the product is said to do about disease in people. The other turns on function: whether it may be given to people to change how the body works through a pharmacological, immunological or metabolic action. A product caught by either limb is a medicinal product.
What follows if it is. Regulation 46 deals with products that have no UK authorisation. It says a person “may not sell or supply, or offer to sell or supply, an unauthorised medicinal product”. It also bars manufacturing or assembling one, or procuring its sale, supply, manufacture or assembly, where the person knows or has reasonable cause to believe it is to be sold or supplied in breach of that rule. Regulation 47 makes a breach an offence: on indictment, “a fine, to imprisonment not exceeding two years or to both.”
Advertising. Regulation 279 says a person “may not publish an advertisement in Great Britain for a medicinal product” unless a UK marketing authorisation, a temporary authorisation, a certificate of registration or a traditional herbal registration is in force for it. Regulation 303 makes a breach of the advertising rules an offence, with the same two-year maximum on indictment.
The narrow exception. Regulation 167 covers unlicensed “specials”: made to a prescriber’s specification for the special needs of their own patient, and never advertised. It serves one patient at a time; it is not a route to a market.
| Provision | What it covers | Maximum on indictment |
|---|---|---|
| Human Medicines Regulations 2012, reg 2 | Defines a medicinal product, by presentation or by function | Definition only |
| Reg 46(1) | Selling or supplying, or offering to, an unauthorised medicinal product | 2 years, a fine or both (reg 47) |
| Reg 46(4) and (5) | Manufacturing, assembling or procuring the sale of one meant for unlawful sale | 2 years, a fine or both (reg 47) |
| Reg 279 | Advertising a medicinal product with no UK authorisation in force | 2 years, a fine or both (reg 303) |
| Reg 167 | Specials for an individual patient, made to a prescriber’s specification, unadvertised | An exception, not an offence |
| Misuse of Drugs Act 1971, Sch 2 | Controlled drugs, Classes A to C | BPC-157 is not listed |
02How does the MHRA decide whether a BPC-157 product is a medicine?
The MHRA does not rule on substances in the abstract. Its Guidance Note 8 says: “The MHRA only classifies finished products and not individual substances and ingredients.”
Consistent with that, we found no MHRA ruling on BPC-157 as such. Each product is judged on its own facts. The guidance lists what the MHRA weighs: the ingredients’ pharmacological, immunological or metabolic properties, the composition, the form (“capsule, tablet, injection, etc.”), the way it is used, the product literature and testimonials, and “the risks which use of the product may pose.”
Presentation. Among the kinds of marketing that the MHRA says may suggest a medicine are “references to medical conditions”, comparison with licensed medicines, and “references to medical and / or clinical research and testing”.
Function. For the second limb, the guidance quotes the European Court of Justice: the authorities “must decide on a case-by-case basis, taking account of all the characteristics of the product, in particular its composition, its pharmacological, immunological or metabolic properties”, as well as how it is used and the risks its use may entail.
What the MHRA said in 2026. In a statement to STV News in March 2026, the MHRA’s head of borderlines said the agency disregards “research purposes” claims “if it is clear that such claims are being used as an attempt to avoid medicines regulations.” The statement added that where a product is classified as a medicine and is not appropriately authorised, the MHRA takes compliance action, “including the removal of the product from the UK market where necessary.” It did not name BPC-157. More on labels: what “research use only” means.
Is any BPC-157 product licensed in the UK? We found none. On 18 November 2026 the emc returned “No search results” for BPC-157; the same search for somatropin returned 21. In a 2026 briefing, FDA staff reported that a globalEDGE search “did not yield” BPC-157 “as a component of an approved product in any country”. We could not run the MHRA Products search, which needs a browser.
03What have UK authorities done, and when?
A dated record, from the sports listing to the 2026 enforcement wave. Press reports are marked.
| Date | Who | What happened |
|---|---|---|
| 20 Oct 2021 | UK Anti-Doping | Tells athletes that BPC-157 “has now been listed as a prohibited substance” on WADA’s 2022 List |
| 1 Jan 2022 | WADA | The 2022 List takes effect, with BPC-157 named in class S0 |
| 25 Feb 2026 | MHRA Criminal Enforcement Unit | Announces raids on a farm near Sleaford and a house in Grantham, believed to be used to make and distribute unlicensed weight-loss medicines “as well as peptide products” |
| 19 Mar 2026 | MHRA, statement to STV News (press report) | Says it disregards “research purposes” claims used to avoid medicines regulations |
| 15 Apr 2026 | MHRA, quoted by Aesthetics Journal (press report) | Confirms that a clinic website offering peptide treatments, BPC-157 among them, made medicinal claims, which is not permitted, and says it is investigating |
| 12 May 2026 | MHRA | Replaces Guidance Note 8 with an amended version |
| 28 May 2026 | MHRA Criminal Enforcement Unit | Raids an estate near Northampton believed to make unlicensed weight-loss medicines “as well as peptide products”; two arrests |
| 2 Jul 2026 | MHRA | Updates its borderline-products guidance |
| 18 Nov 2026 | Our check | No UK legislation and no published MHRA determination naming BPC-157 found |
Neither MHRA press release names BPC-157. They show where enforcement has been aimed: unlicensed manufacture and supply, with peptides alongside weight-loss drugs.
04Is BPC-157 a controlled drug in the UK?
No. BPC-157 is not listed in Schedule 2 to the Misuse of Drugs Act 1971, which sets out Classes A, B and C. We read the whole schedule, as revised on legislation.gov.uk, on 18 November 2026. The peptide hormones that are controlled there, such as somatropin, sit in Class C.
Not being a controlled drug does not settle the medicines question above. The two regimes are separate. The wider picture, including growth hormone and the Psychoactive Substances Act 2016, is on are peptides legal in the UK?
05How is BPC-157 treated in UK sport?
UK sport follows the World Anti-Doping Code. On WADA’s Prohibited List, BPC-157 appears by name in S0, the class for non-approved substances, which are barred in competition and out of it. When the listing was announced, UK Anti-Doping told athletes to stay alert to supplements that market it, “as it is not approved for human consumption.”
Every substance in S0 is a Specified Substance under the List. That affects the length of a sanction, not whether use is a violation. The detail, with cases and dates, is on is BPC-157 banned in sport?
06What changed in 2026?
The law did not change. Enforcement and guidance did.
No new UK law. Some websites describe a 2026 UK order that reclassified BPC-157. We found no such instrument. A legislation.gov.uk search of 2026 titles for “novel therapeutic”, “therapeutic substances” and “peptide” returned no results on 18 November 2026, while the same search for “human medicines” returned 2026 instruments. A full-text search for “BPC-157” returned nothing.
More enforcement. The MHRA’s Criminal Enforcement Unit announced raids in February and May on premises it believed were used to make and distribute unlicensed weight-loss medicines and peptide products.
Positions on the record. The MHRA set out its view of “research purposes” labels and, by press reports, opened an inquiry into clinics’ peptide claims.
Updated guidance. Guidance Note 8 was amended in May and the borderline guidance updated in July.
Outside the UK. The US HHS policy of October 2026 concerns US compounding only; see is BPC-157 legal? for the US and Australia. WADA’s 2027 List, in force from 1 January 2027, adds “peptides” to the examples in S0.
07What we don’t know
How the MHRA would classify a given product. It decides finished products case by case, and we found no published determination naming BPC-157.
The outcome of the clinic inquiry. The MHRA had published nothing on it as of 18 November 2026.
MHRA Products. We could not run its search. Our check for a licensed UK product is the emc result above, plus FDA staff’s globalEDGE search.
Northern Ireland. Parts of these rules differ there, and we have not covered them.
The evidence on BPC-157 itself is in our BPC-157 research guide. Changes are logged in our regulatory changelog.
This is a plain-English summary of public documents, checked on 18 Nov 2026. It is not legal advice.